RecruitingPhase 2Phase 3NCT06341907

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Application of MRD Combined With Personalized Vaccine in the Adjuvant Treatment of Postoperative Recurrence Prevention of Epithelial Ovarian Cancer

Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Enrollment

10 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Epithelial Ovarian Cancer

Summary

The goal of this clinical trial is as follows:(1) Establish a clinical technical system for ctDNA dynamic monitoring of MRD in postoperative EOC patients, providing a new technical means for postoperative recurrence prevention and monitoring of EOC patients.(2) Establish a clinical technical system for adjuvant treatment of postoperative recurrence prevention for EOC patients with conventional protocols combined with personalized vaccines, so as to provide a new treatment method for postoperative recurrence prevention for EOC patients, with a view to obtaining a better survival prognosis.(3) To establish and improve the prediction process of Neoantigen for ovarian cancer and the in vitro evaluation system of the effectiveness of neoantigen vaccine, achieve independent innovation of tumor neoantigen vaccine treatment technology, and cultivate a group of technical forces to master the development of modern tumor vaccine drugs.(4) The new technology system has been promoted and applied in 5 hospitals in the province.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a personalized cancer vaccine combined with ongoing monitoring of residual tumor DNA in the blood (called MRD testing) can prevent ovarian cancer from coming back after surgery. **You may be eligible if...** - You have stage II, III, or IV epithelial ovarian cancer that has been surgically removed - Your MRD (minimal residual disease) blood test was positive after surgery, meaning small traces of cancer DNA were detected in your blood - You are between 18 and 70 years old - You are in generally good health (ECOG 0 or 1) - Your blood counts and organ function are within acceptable limits **You may NOT be eligible if...** - You have HIV, active hepatitis B or C, or uncontrolled heart or brain conditions - You have a history of organ or bone marrow transplant - You have autoimmune disease or immune deficiency - You have a bleeding disorder or active gastrointestinal bleeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.